Literature DB >> 29850387

Angioedema: A Life-threatening Complication of Tissue Plasminogen Activator.

Muhammad Khalid1, Majd Kanaa1, Yazan Alkawaleet1, Muhammad Talha Ayub2.   

Abstract

Angioedema is a localized, non-pitting, non-dependent, submucosal, and subcutaneous swelling resulting from the extravasation of fluid into the interstitium due to the increased production of plasma kinins and histamine. It can present with urticaria or anaphylaxis and is usually associated with angiotensin-converting enzyme inhibitors (ACEis), complement deficiencies, or the side effects of tissue plasminogen activator (tPA). Orolingual angioedema following tPA for acute ischemic stroke is a transient, self-resolving hemifacial swelling contralateral to neurological deficits that can rarely progress to the airway, compromising it and leading to a life-threatening situation if not managed promptly.

Entities:  

Keywords:  angioedema; angiotensin converting enzyme; t-pa (tissue plasminogen activator )

Year:  2018        PMID: 29850387      PMCID: PMC5973511          DOI: 10.7759/cureus.2392

Source DB:  PubMed          Journal:  Cureus        ISSN: 2168-8184


  10 in total

1.  Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase.

Authors:  J Rudolf; M Grond; S Schmülling; M Neveling; W Heiss
Journal:  Neurology       Date:  2000-08-22       Impact factor: 9.910

2.  Thrombolysis with alteplase for acute ischaemic stroke in the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST): an observational study.

Authors:  Nils Wahlgren; Niaz Ahmed; Antoni Dávalos; Gary A Ford; Martin Grond; Werner Hacke; Michael G Hennerici; Markku Kaste; Sonja Kuelkens; Vincent Larrue; Kennedy R Lees; Risto O Roine; Lauri Soinne; Danilo Toni; Geert Vanhooren
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

3.  Orolingual angioedema after alteplase therapy of acute ischaemic stroke: incidence and risk of prior angiotensin-converting enzyme inhibitor use.

Authors:  S-Y Lin; S-C Tang; L-K Tsai; S-J Yeh; Y-J Hsiao; Y-W Chen; K-H Chen; B-S Yip; L-J Shen; F-L Lin Wu; J-S Jeng
Journal:  Eur J Neurol       Date:  2014-06-09       Impact factor: 6.089

4.  Life-threatening orolingual angioedema during thrombolysis in acute ischemic stroke.

Authors:  S T Engelter; F Fluri; C Buitrago-Téllez; S Marsch; A J Steck; S Rüegg; P A Lyrer
Journal:  J Neurol       Date:  2005-09-27       Impact factor: 4.849

5.  Thrombolysis for acute ischemic stroke: results of the Canadian Alteplase for Stroke Effectiveness Study.

Authors:  Michael D Hill; Alastair M Buchan
Journal:  CMAJ       Date:  2005-05-10       Impact factor: 8.262

6.  A Novel Approach to the Treatment of Orolingual Angioedema After Tissue Plasminogen Activator Administration.

Authors:  Lesley Pahs; Chris Droege; Hilary Kneale; Arthur Pancioli
Journal:  Ann Emerg Med       Date:  2016-05-10       Impact factor: 5.721

7.  Benign angioedema after thrombolysis for acute stroke.

Authors:  N I Papamitsakis; J Kuyl; H L Lutsep; W M Clark
Journal:  J Stroke Cerebrovasc Dis       Date:  2000 Mar-Apr       Impact factor: 2.136

8.  Hemi-orolingual angioedema and ACE inhibition after alteplase treatment of stroke.

Authors:  M D Hill; T Lye; H Moss; P A Barber; A M Demchuk; N J Newcommon; T L Green; C Kenney; A Cole-Haskayne; A M Buchan
Journal:  Neurology       Date:  2003-05-13       Impact factor: 9.910

9.  Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian Acute Stroke Study Investigators.

Authors:  W Hacke; M Kaste; C Fieschi; R von Kummer; A Davalos; D Meier; V Larrue; E Bluhmki; S Davis; G Donnan; D Schneider; E Diez-Tejedor; P Trouillas
Journal:  Lancet       Date:  1998-10-17       Impact factor: 79.321

10.  Incidence, predictors and clinical characteristics of orolingual angio-oedema complicating thrombolysis with tissue plasminogen activator for ischaemic stroke.

Authors:  Robert Hurford; Sean Rezvani; Mohammad Kreimei; Annie Herbert; Andy Vail; Adrian R Parry-Jones; Chris Douglass; Jane Molloy; Hana Alachkar; Pippa J Tyrrell; Craig J Smith
Journal:  J Neurol Neurosurg Psychiatry       Date:  2014-07-12       Impact factor: 10.154

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.